ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,420.26
-0.22%
Dow Jones
40,003.59
0.34%
Gold vs US Dollar
2,413.935
1.50%
Brent Oil
83.76
0.67%
Bitcoin
66,745.65
2.31%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Acumen Pharmaceuticals Inc (ABOS)

  7. Acumen Pharmaceuticals Inc (ABOS) News

Acumen Pharmaceuticals (ABOS)

Acumen Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ABOS
DateTimeSourceHeadlineSymbolCompany
14/05/202421:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABOSAcumen Pharmaceuticals Inc
14/05/202412:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
14/05/202412:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
13/05/202421:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
08/05/202422:47GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
08/05/202413:00GlobeNewswire Inc.Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
07/05/202421:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
16/04/202413:00GlobeNewswire Inc.Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
04/04/202413:00GlobeNewswire Inc.Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
26/03/202411:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
21/03/202412:00GlobeNewswire Inc.Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
19/03/202420:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
12/03/202420:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS DaysNASDAQ:ABOSAcumen Pharmaceuticals Inc
08/03/202413:50GlobeNewswire Inc.Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
21/02/202413:00GlobeNewswire Inc.Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
14/02/202413:32Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABOSAcumen Pharmaceuticals Inc
01/02/202422:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
01/02/202422:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
01/02/202412:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
01/02/202412:00GlobeNewswire Inc.Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development OfficerNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202400:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202400:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202400:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202400:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202400:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
19/01/202421:36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
19/01/202421:35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
18/01/202421:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
18/01/202421:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
18/01/202421:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ABOS

Your Recent History

LSE
ENET
Ethernity Networks
LSE
VAST
Vast Resources
LSE
TERN
Tern
LSE
MIN
Minoan
LSE
EZJ
Easyjet
LSE
BP.
Bp
LSE
BIRD
Blackbird
LSE
GKP
Gulf Keystone Petroleum
LSE
CUSN
Cornish Metals
LSE
SRSP
Sirius Petroleum
LSE
AAZ
Anglo Asian Mining
LSE
JLP
Jubilee Metals
LSE
THG
Thg
LSE
SYME
Supply@me Capital
LSE
CHRY
Chrysalis Investments
LSE
POS
Plexus
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved